Backed by Eli Lilly, a little-known and secretive Chinese biotech fills the tank as it heads to the clinic

A Chinese biotech backed by Lilly Asia Ventures just got some new cash to throw around.

Lynk Pharmaceuticals pulled in $50 million in a recently completed Series B, the biotech announced Friday, a little over three years after launch. The company plans to use the funds to support Phase I and Phase II studies for multiple pipeline programs, though it didn’t specify for which.